UNSPSC 51202403: Belimumab

This classification denotes a monoclonal antibody with the molecular formula C6714H10428O2102S52, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 73B0K5S26A, more generally known as belimumab. European Medicines Agency schedules belimumab in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB25607. The term BELIMUMAB is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 18, No. 1, 2004, list 51.

Most nations, for tariff and trade purposes, schedule Belimumab under HS 30021091 and SITC 54163. SMILES:. As of Q4 2014, BELIMUMAB remains US FDA's Preferred Term for this commodity.. Belimumab bears US NLM identifiers UMLS ID C1723401 and NCI Concept Code C91385.

UNSPSC 51202403 Belimumab, a Commodity code, does not align with the state and local procurement opportunities recently posted under this category. The source records show solicitations for naloxone and drug deactivation systems (Seminole County, Florida), direct-to-manufacturer prescription programs (Texas HHS Commission), medical and first aid supplies for emergency response (City of Tampa), and generic multi-source pharmaceuticals and OTC products (Minnesota Multistate Cooperative Purchasing Alliance). None of these opportunities concern belimumab, a biologic immunosuppressant indicated for systemic lupus erythematosus and lupus nephritis. The code shows little relevant recent activity in state and local procurement channels.

The mismatch suggests either a cataloging error in the UNSPSC tagging or a fundamental disconnect between the code's nominal scope and how state and local agencies currently use it. Businesses tracking belimumab procurement should verify whether state and local health systems, Medicaid agencies, or hospital networks source this drug through formulary or purchasing-group contracts prior to investing in business development under this code. The recent opportunities in the source represent high-volume, lower-cost consumables and pharmaceuticals—a different procurement universe than specialty biologics.